Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Marschall, HU; Wagner, M; Zollner, G; Fickert, P; Lackner, C; Thorell, A; Trauner, M.
Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients.
Dig Dis. 2011; 29(1):117-118
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Fickert Peter
Lackner Karoline
Trauner Michael
Wagner Martin
Zollner Gernot

Dimensions Citations:

Plum Analytics:
Bile acids have recently been identified as major integrators of hepatic fatty acid and triglyceride metabolism. We explored potential mechanism(s) of action of ursodeoxycholic acid (20 mg/kg/day in 3 weeks) in 40 morbidly obese patients (mean BMI >40 kg/m(2)) with suggested fatty liver disease awaiting bariatric surgery. At follow-up half a year after surgery, patients had decreased their BMI by approximately 10 kg/m(2), which resulted in significant improvements of liver function tests, insulin sensitivity and glucose tolerance. Copyright © 2011 S. Karger AG, Basel.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Dyslipidemias - complications Dyslipidemias - drug therapy
Fatty Liver - complications Fatty Liver - drug therapy
Female -
Glucose Tolerance Test -
Humans -
Insulin Resistance -
Male -
Obesity, Morbid - complications
Ursodeoxycholic Acid - therapeutic use

Find related publications in this database (Keywords)
Insulin resistance
Glucose tolerance
Bariatric surgery
© Meduni Graz Impressum